Pfizer today
- 52 weeks
- 20.92 dollars
▼
$ 31.54
- Profit
- 7.37 %
- P/E ratio.
- 16.55
- The target price
- $ 29.17
A Profit It exceeds 7.5 % of the pharmaceutical giant such as Pfizer Inc. Nyse: pfe Certainly draws the attention of investors looking for income.
Such a great return often refers to a mature and stable company that generously equivalent to its shareholders. However, a closer look reveals a complex image of the New York -based drug maker.
Do these impressive payments actually represent a safe income flow, or does it hide the basic concerns regarding the company’s future growth path Financial flexibility With continued development in the rapid health care sector?
7.5 % PFIZER Declaration Decer
Pfizer B commitment Capital return to shareholders It is clear in its current annual profits of $ 1.72 per share. This translates into a quarterly payment of $ 0.43 per share. As of May 22, 2025, this revenue is 7.5 %. For context, the profit distributions return is the annual profit payments as a percentage of the current price of the share, providing a measure of the return that the investor can expect.
Pfizer profit payments
- Profit
- 7.37 %
- Annual profit distributions
- $ 1.72
- Record of profit distributions
- 16 years old
- An annual profit growth for 3 years
- 2.50 %
- The percentage of profit distribution
- 124.64 %
- Pay the following profits
- June 13
Date of profit distribution
PFIZER has a noticeable busy record, as his profits have increased for 16 years in a row, a history that often appeals to investors who are looking for reliable and increasing income.
It is important to a reliable evaluation of any profits, which is to understand the company’s compensation rates. the The percentage of profit distribution It measures the percentage of profits or cash flow paid to shareholders as profits. Pfizer profits consumes about 47.69 % of the cash flow. The payment rate of less than 100 % indicates that the cash flow generally indicates that the company generates sufficient money to cover profit payments, which is a positive sign of sustainability.
However, when looking at its late profits for 12 months, the payment rate is 124.64 %. This number indicates that, based on recently reported profits, the company paid more profits than it got. This contrast highlights the importance of future profit growth and cost management in maintaining profit distributions at the current levels.
Click on Revenue: The highest Vizar test
The financial performance in the last Pfizer reveals the transfer of revenue dynamics. In the first quarter of 2025, Total revenue It decreased by 8 % year on an annual basis to $ 13.7 billion, due primarily to a 75 % decrease in Paxlovid sales with Covid-19 demand, creating comparisons from difficult growth. Moreover, Pfizer faces a long long obstacle: the company on the edge of the imminent patent shelf.
The main drugs such as Eliquis (losing exclusivity in April 2028), Prenar, IBRANCE and XTandi (confrontation of competition in 2026-2027) A strong defensive strategy To develop new revenue flows.
How PFIZER aims to fill the revenue engine
In response to these revenue pressures, Pfizer pursues a strategic activity focused on the renovation of pipelines, with a clear focus on tumors. The cornerstone was in this strategy 43 billion dollars in acquisition From Seagen in March 2023. This highly built acquisition of PFIZER capabilities in anti -drug federations, a promising category of cancer treatments, and the Seagen portfolio of $ 3.4 billion contributed to Fayzer’s revenues in the fiscal year 2024.
Recently, in May 2025, Pfizer entered into an exclusive global licensing agreement (except China) with 3SBIO, Inc. For SSGJ-707, which is an investigative anti-aid body targeting PD-1 and Vegf for multiple types of cancer. The deal includes a batch of $ 1.25 billion, and its value may reach $ 6 billion in total, confirming the commitment of Pfizer to external innovation sources. The company aims to launch eight new cancer drugs by 2030.
Positive developments in the Oncology pipeline include the approval of the US Food and Drug Administration (FDA) on Adcetris in large lymph n glands and encouraging clinical data for Padcev in urine cancer. Talzenna also showed a generally positive survival data in prostate cancer, although FDA’s advisory committee raised questions about its broader application.
Outside oncology, the Abrysvo RSV vaccine witnessed extensive recommendations in Europe and the United States, which may increase its arrival in the market. However, the pharmaceutical development path is not without setbacks, as it is clear from stopping the Danuglipron GLP-1 candidate in April 2025.
Payzer payments: a sustainable reward or a crop trap?
Fayzer stock expectations today
$ 29.17
25.00 % upModerate purchase
Based on 15 analyst classifications
| The current price | 23.33 dollars |
|---|---|
| High expectations | $ 34.00 |
| Average expectations | $ 29.17 |
| Low expectations | $ 24.00 |
Fayzer stock forecast details
There is no doubt that the current Pfizer profit revenue is 7.5 %, undoubtedly provides an excellent income component for Investment Governor. This payment is supported by a date of consistent growth, and most importantly, generating the company’s cash flow. However, this attractive return exists in the context of the major operational and strategic challenges. The decrease in the revenue of the Covid-19 products and the imminent loss in the uniqueness of many major drugs creates a significant obstacle for future growth.
Although this may seem, the company does not stop fixed; Total cost reduction measures are carried out, and large investments are made to renew the pipeline youth, especially in the high -capacity tumor sector. The success of the executions of this strategic plan will be very important in determining the ability of Pfizer to move in the end of the upcoming patents and return to a path Sustainable revenue growth and profits.
For investors, the decision depends on the balance of the current high return against the uncertainty associated with the transmission of a multi -year Peter. The validity of profits in the long term depends on its current relative level in the end on the successful implementation of it Growth strategy.
Before you think about Pfizer, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before hunting the broader market … PFIZER was not in the list.
While Pfizer currently has a moderate purchase classification between analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Discover the 7 best shares of Amnesty International Investment now. This exclusive report highlights companies that lead the artificial intelligence revolution and the formation of the future of technology in 2025.
